FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHA Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor [NCT06065540]RESEARCHSemaglutide in Alcohol Use Disorder [NCT07949474]RESEARCHEffects of NNC0194-0499, Cagrilintide, and Semaglutide Alone or in Combinations on Liver Damage and Alcohol Use in People With Alcohol-related Liver Disease [NCT06409130]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]NEWS‘Selling and marketing snake oil’: The debate over compounded GLP-1sRESEARCHSemaglutide Effects on Sperm Concentration in Overweight Infertile Men [NCT07946796]RESEARCHTirzepatide for the REduction of AceTazolamide in Idiopathic Intracranial Hypertension [NCT07946315]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHA Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor [NCT06065540]RESEARCHSemaglutide in Alcohol Use Disorder [NCT07949474]RESEARCHEffects of NNC0194-0499, Cagrilintide, and Semaglutide Alone or in Combinations on Liver Damage and Alcohol Use in People With Alcohol-related Liver Disease [NCT06409130]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]NEWS‘Selling and marketing snake oil’: The debate over compounded GLP-1sRESEARCHSemaglutide Effects on Sperm Concentration in Overweight Infertile Men [NCT07946796]RESEARCHTirzepatide for the REduction of AceTazolamide in Idiopathic Intracranial Hypertension [NCT07946315]

Para fines de investigación únicamente. Aviso completo →

Volver a Biblioteca de Investigación
PubMedHuman TrialSujetos Humanos

Discontinuation and Reinitiation of Dual-Labeled GLP-1 Receptor Agonists Among US Adults With Overweight or Obesity.

Rodriguez Patricia J, Zhang Vincent, Gratzl Samuel, Do Duy, Goodwin Cartwright Brianna, Baker Charlotte, Gluckman Ty J, Stucky Nicholas, Emanuel Ezekiel J
JAMA network open2025DOI: 10.1001/jamanetworkopen.2024.57349
GLP-1 receptor agonistsliraglutidesemaglutidetirzepatide

Puntuación de Calidad

6/10

Citas

0

Sujetos

Humano

Análisis de Peptide Contacts

Study Design

Human trial data is the most directly translatable evidence for therapeutic applications. The physiological responses observed here reflect real human biology, not extrapolations from animal models.

Our Assessment

Quality Assessment: 6/10 — This is a solidly conducted study with clear methodology and reasonable conclusions. Minor limitations exist (noted below) but don't undermine the core findings. The evidence here is reliable enough to inform both research direction and practical decision-making.

Findings in Context

These findings advance our understanding of GLP-1 receptor agonists, liraglutide, semaglutide, tirzepatide in meaningful ways. The human-subjects design makes these results particularly relevant for clinical translation.

On the Limitations

Every study has limitations, and being transparent about them is what separates good science from hype. These limitations don't invalidate the findings — they define the boundaries of what we can confidently conclude.

The Takeaway

Bottom line: Decent human data on GLP-1 receptor agonists, liraglutide, semaglutide, tirzepatide. Not the final word, but a meaningful data point that adds to the weight of evidence.

Encuentros Clave

The study found that patients without type 2 diabetes had higher discontinuation rates of GLP-1 receptor agonists compared to those with type 2 diabetes. Weight loss and higher income were associated with lower discontinuation rates, while gastrointestinal adverse events increased the risk of discontinuation.

Limitaciones

The retrospective nature of the study limits causal inference, and the reliance on electronic health records may introduce selection bias or missing data issues.

Cómo Interpretar esta Investigación

1

Look for the sample size — larger studies produce more reliable results. Single-digit sample sizes warrant caution.

2

Check whether the study was funded by a pharmaceutical company or conducted independently, as funding sources can influence study design and reporting.

3

Examine the primary endpoint — did the study measure what actually matters clinically, or a proxy marker?

4

Statistical significance (p < 0.05) does not always mean clinical significance. Look at the actual effect size.

5

Always consult a qualified healthcare provider before making treatment decisions based on research findings. Published research is not a substitute for personalized medical advice.

Análisis de Peptide Contacts

Exploring the Adherence Challenges and Influencing Factors of GLP-1 Receptor Agonists Among Patients With Overweight or Obesity

GLP-1 receptor agonistsliraglutidesemaglutidetirzepatide

Adherence Challenges to GLP-1 Receptor Agonists: Insights from a Large-Scale Retrospective Study

Published: May 16, 2026 | Source: JAMA network open (2025) | Category: GLP-1 receptor agonists, liraglutide, semaglutide, tirzepatide

Overview

A recent study published in the JAMA Network Open has shed light on the adherence challenges faced by patients using glucagon-like peptide-1 (GLP-1) receptor agonists for weight management. The research reveals that individuals without type 2 diabetes are more likely to discontinue their GLP-1 treatment compared to those with the condition, highlighting significant differences in patient adherence patterns.

Study Background

GLP-1 receptor agonists have become a cornerstone of obesity and diabetes management due to their effectiveness in weight loss and glycemic control. However, ensuring long-term adherence remains a critical challenge. Previous studies have noted varying levels of discontinuation rates but lacked detailed insights into the factors influencing these decisions among patients with overweight or obesity.

What the Research Found

The study analyzed data from 125,474 adults who started using GLP-1 receptor agonists (liraglutide, semaglutide, or tirzepatide) between January 1, 2018, and December 31, 2023. Among these patients, 61% had type 2 diabetes. The research found that one-year discontinuation rates were significantly higher for those without type 2 diabetes (64.8%) compared to those with the condition (46.5%). Furthermore, weight loss was associated with lower risks of discontinuing treatment: a 1% reduction in weight from baseline correlated with a 3.1% and 3.3% decrease in discontinuation risk for patients with and without type 2 diabetes, respectively.

What This Means for Peptide Users

The findings suggest that adherence to GLP-1 receptor agonists is influenced by the presence of type 2 diabetes and weight loss outcomes. Patients without type 2 diabetes may face additional challenges in maintaining long-term treatment adherence due to factors such as perceived necessity or side effects like gastrointestinal issues, which can be mitigated through better patient education and support.

Limitations and Caveats

The retrospective nature of the study limits its ability to establish causality between variables. Additionally, reliance on electronic health records introduces potential biases related to data completeness and accuracy. These limitations underscore the need for further research using prospective designs to confirm these findings and explore additional influencing factors such as patient education levels and socioeconomic status.

How This Compares to Previous Research

Previous studies have also noted higher discontinuation rates among patients with overweight or obesity, but this study provides a more nuanced understanding by stratifying results based on the presence of type 2 diabetes. The association between weight loss and adherence aligns with earlier research that emphasized the importance of treatment efficacy in sustaining patient engagement.

Our Analysis

PeptideVault views this study as an important contribution to our understanding of GLP-1 receptor agonist adherence, particularly among patients without type 2 diabetes. While it highlights critical areas for improvement, such as addressing gastrointestinal side effects and enhancing patient education, the retrospective design limits definitive conclusions about causality.

Key Takeaways

  • Higher Discontinuation Rates: Patients without type 2 diabetes have higher discontinuation rates compared to those with the condition.
  • Weight Loss Impact: Weight loss is associated with improved adherence to GLP-1 receptor agonists.
  • Gastrointestinal Side Effects: These are significant factors in treatment discontinuation, underscoring the need for better management strategies.

Original Source

Citation: Rodriguez Patricia J, Zhang Vincent, Gratzl Samuel et al. (2025). Discontinuation and Reinitiation of Dual-Labeled GLP-1 Receptor Agonists Among US Adults With Overweight or Obesity.. JAMA network open. DOI: 10.1001/jamanetworkopen.2024.57349

Access:

---

This article is for informational and research purposes only. PeptideVault summarizes and analyzes published research. Always consult a licensed healthcare provider.

Nota del Editor

Este análisis fue escrito por el equipo de investigación de Peptide Contacts para hacer hallazgos complejos accesibles a la comunidad de péptidos. Se anima a los lectores a revisar el paper fuente para metodología y datos completos. Para más sobre GLP-1 receptor agonists, explore nuestros guias de investigación.

Cita

Rodriguez Patricia J, Zhang Vincent, Gratzl Samuel et al.. (2025). Discontinuation and Reinitiation of Dual-Labeled GLP-1 Receptor Agonists Among US Adults With Overweight or Obesity.. JAMA network open. https://doi.org/10.1001/jamanetworkopen.2024.57349

Ver texto completo en PubMed

Papers Relacionados

Explorar más

Este contenido se deriva de investigación revisada por pares para fines educativos solo. No constituye consejo médico. Consulte siempre a un proveedor de atención médica calificado antes de usar cualquier terapia basada en péptidos.